Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INS1202 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Participants with sporadic amyotrophic lateral sclerosis (sALS) will be administered INS1202, IT injection at dose level 1 on Day 1. |
| Cohort 2 | EXPERIMENTAL | Participants with either sALS or SOD1-ALS, will be administered INS1202 via IT injection at dose level 2 on Day 1. |
| Cohort 3 | EXPERIMENTAL | Participants with either sALS or SOD1-ALS, will be administered INS1202 via IT injection at dose level 3 on Day 1. |
| Name | Type | Description |
|---|---|---|
| INS1202 | GENETIC | Suspension for injection. |
Key Inclusion Criteria: - * Participant with body mass index (BMI) ≥18 kilograms per square meter (kg/m\^2). * Participant with symptomatic ALS as diagnosed by Gold Coast diagnostic criteria. * Sporadic ALS cohorts: Negative testing for known monogenic mutations associated with familial ALS. * SOD1...
INS1202 is an investigational gene therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. It is administered as a single intrathecal injection and is currently in Phase 1 clinical development.
INS1202 targets the SOD1 gene, which is associated with a form of amyotrophic lateral sclerosis. By targeting this gene, the therapy aims to address the underlying genetic cause of the disease. It is delivered via a single intrathecal injection.
INS1202 is being developed by Insmed Incorporated, a biopharmaceutical company listed on the NASDAQ under the ticker symbol INSM. The company is conducting a Phase 1 clinical trial to evaluate the safety and pharmacodynamics of the therapy in patients with ALS.
INS1202 is in Phase 1 clinical development. It is an investigational gene therapy that has not yet been approved by regulatory authorities. A Phase 1 trial is currently recruiting participants to assess its safety and pharmacodynamics in individuals with amyotrophic lateral sclerosis.
INS1202 is being studied in a Phase 1 clinical trial with the identifier NCT07290062. This trial is investigating the safety and pharmacodynamics of a single intrathecal injection of INS1202 in participants with amyotrophic lateral sclerosis. The study is recruiting up to 23 participants in the United States.